

Wykaz znaczących publikacji (2003-2006)

1. Conato C., Kamysz W., Kozłowski H., Łuczkowski M., Maćkiewicz Z., Mancini F., Młynarz P., Remelli M., Valensin D., Valensin G. Cu(II) ion coordination to unprotected pentadecapeptide containing two His residues: Competition between the terminal amino and the side-chain imidazole nitrogen donors. *Eur. J. Inorg. Chem.*, 2003;1694-1702 - 24 pkt.
2. Giacometti A., Cirioni O., Ghiselli R., Mocchegiani F., D'Amato G., Del Prete M.S., Orlando F., Kamysz W., Łukasiak J., Saba V., Scalise G. Administration of protegrin peptide IB-367 to prevent endotoxin-induced mortality in bile duct-ligated rats. *Gut*, 2003;6:885-889 - 24 pkt.
3. Cirioni O., Giacometti A., Ghiselli R., Dell'Acqua G., Gov Y., Kamysz W., Łukasiak J., Mocchegiani F., Orlando F., D'Amato G., Saba V., Scalise G. Prophylactic efficacy of intraperitoneal temporin A combined with topical RNAIII-inhibiting peptide in a subcutaneous rat pouch model of graft infection due to staphylococci with intermediate resistance to glycopeptides. *Circulation*, 2003;108:767-771 - 24 pkt.
4. Kamysz W., Okrój M., Łukasiak J. Novel properties of antimicrobial peptides. *Acta Biochim. Pol.*, 2003;2:461-469 - 10 pkt.
5. Giacometti A., Cirioni O., Kamysz W., D'Amato G., Silvestri C., Del Prete M.S., Łukasiak J., Scalise G. Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH₂ against multidrug-resistant nosocomial isolates of *Acinetobacter baumannii*. *Peptides*, 2003;24(9):1315-1318 - 20 pkt.
6. Giacometti A., Cirioni O., Ghiselli R., Mocchegiani F., Viticchi C., Orlando F., D'Amato G., Del Prete M.S., Kamysz W., Łukasiak J., Saba V., Scalise G.: Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock. *Peptides*, 2003;24(11):1747-1752 - 20 pkt.
7. Kamysz W., Okrój M., Łempicka E., Ossowski T., Łukasiak J. Fast and efficient purification of synthetic peptides by solid-phase extraction. *Acta Chromatographica*, 2004;14:180-186 - 10 pkt.
8. Cirioni O., Giacometti A., Ghiselli R., Orlando F., Kamysz W., D'Amato G., Mocchegiani F., Łukasiak J., Silvestri C., Saba V., Scalise G. Potential therapeutic role of histatin derivative P-1 13d in experimental rat models of *Pseudomonas aeruginosa* sepsis. *J Infect Dis*, 2004;190:356-364 - 24 pkt.
9. Giacometti A., Cirioni O., Kamysz W., D'Amato G., Silvestri C., Del Prete M. S., Łukasiak J., Scalise G. In vitro activity and killing effect of the synthetic hybrid cecropin A-melittin peptide CA(1-7)M(2-9)NH₂ on methicillin-resistant nosocomial isolates of *Staphylococcus aureus* and interactions with clinically used antibiotics. *Diagn Microbiol Infect Dis*. 2004;49(3):197-200 - 20 pkt.
10. Giacometti A., Cirioni O., Ghiselli R., Orlando F., D'Amato G., Kamysz W., Mocchegiani F., Sisti V., Silvestri C., Rocchi M., Łukasiak J., Saba V., Scalise G. Temporin A soaking in combination with intraperitoneal linezolid prevents vascular graft infection in a subcutaneous rat pouch model of infection with *Staphylococcus epidermidis* with intermediate resistance to glycopeptides. *Antimicrob. Agents Chemother.*, 2004;48(8):3162-3164 - 24 pkt.
11. Giacometti A., Ghiselli R., Cirioni O., Mocchegiani F., D'Amato G., Orlando F., Sisti V., Kamysz W., Silvestri C., Naldoski P., Rocchi M., Łukasiak J., Saba V., Scalise G. Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models. *J Antimicrob Chemother.*, 2004;54(3):654-660 - 24 pkt.

12. Giacometti A., Cirioni O., Ghiselli R., Orlando F., Kamysz W., Rocchi M., D'Amato G., Mocchegiani F., Silvestri C., Łukasiak J., Saba V., Scalise G.: Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. *Peptides*, 2005;26(2):307-316 - 20 pkt.
13. Giacometti A., Cirioni O., Kamysz W., D'Amato G., Silvestri C., Del Prete M.S., Licci A., Łukasiak J., Scalise G.: In vitro activity and killing effect of tmporin A on nosocomial isolates of *Enterococcus faecalis* and interactions with clinically used antibiotics. *JAntimicrob Chemother.* 2005;55(2):272-274 - 24 pkt.
14. Giacometti A., Cirioni O., Kamysz W., D'Amato G., Silvestri C., Del Prete M.S., Licci A., Riva A., Łukasiak J., Scalise G.: In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. *Antimicrob. Agents Chemother.*, 2005;49(3):1249-1252 - 24 pkt.
15. Giacometti A., Cirioni O., Kamysz W., Silvestri C., Del Prete M.S., Licci A., D'Amato G., Łukasiak J., Scalise G.: In vitro activity and killing effect of citropin 1.1 against gram-positive pathogens causing skin and soft tissue infections. *Antimicrob Agents Chemother.*, 2005;49(6):2507-2509 - 24 pkt.
16. Kamysz W., Królicka A., Bogucka K., Ossowski T., Łukasiak J., Łojkowska E.: Antibacterial activity of synthetic peptides against plajit pathogenic *Pectobacterium* species. *J Phytopathol.*, 2005;153:313-317 - 15 pkt.
17. Giacometti A., Cirioni O., Kamysz W., D'Amato G., Silvestri C., Licci A., Nadolski P., Riva A., Łukasiak J., Scalise G.: In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. *Int. J. Antimicrob. Agents.* 2005;26(3):235-240 - 24 pkt.
18. Giacometti A., Cirioni O., Kamysz W., Silvestri C., Del Prete M.S., Licci A., D'Amato G., Łukasiak J., Scalise G.: In vitro activity of citropin 1.1 alone and in combination with clinically used antimicrobial agents against *Rhodococcus equi*. *JAntimicrob Chemother.* 2005;55(7):1153-1156 - 24 pkt.
19. Cirioni O., Giacometti A., Ghiselli R., Kamysz W., Orlando F., Mocchegiani F., Silvestri C., Licci A., Łukasiak J., Saba V., Scalise G.: Temporin A alone and in combination with imipenem reduces lethality in a mouse model of staphylococcal sepsis. *J. Infect. Dis.* 2005;192(9):1613-1620 - 24 pkt.
20. Giacometti A., Cirioni O., Ghiselli F., Mocchegiani F., Silvestri C., Orlando F., Kamysz W., D'Amato G., Kamysz E., Łukasiak J., Saba V., Scalise G.: Amphibian peptides prevent endotoxemia and bacterial translocation in bile duct-ligated rats. *Crit Care Med.* 2006;34(9):2415-2420 - 24 pkt.
21. Kamysz W., Mickiewicz B., Rodziewicz-Motowidło S., Greber K., Okrój M.: Temporin A and its retro-analogues: synthesis, conformational analysis and antimicrobial activities. *JPept Sci*;12(9):653-662. - 20 pkt.
22. Czajgucki Z., Andruszkiewicz R., Kamysz W.: Structure activity relationship studies on the antimicrobial activity of novel edeine A and D analogues. *JPept Sci*;12(9):653-662. - 20 pkt.
23. Cirioni O., Giacometti A., Ghiselli R., Kamysz W., Orlando F., Mocchegiani F., Silvestri C., Licci A., Chiodi L., Łukasiak J., Saba V., Scalise G.: Ctropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. *Peptides.* 2006;27(6):1210-1216 - 20 pkt.